| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = -$400,000 ) |
| | 2024 | 2022 | SYNERGYS BIOTHERAPEUTICS INC | 3189 DANVILLE BLVD | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R44CA265690 | Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer | 000 | 1 | NIH | 4/9/2024 | -$400,000 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | SYNERGYS BIOTHERAPEUTICS INC | 3189 DANVILLE BLVD | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R44CA265690 | Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer | 001 | 1 | NIH | 3/29/2023 | $0 |
| | 2023 | 2022 | SYNERGYS BIOTHERAPEUTICS INC | 3189 DANVILLE BLVD | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R44CA265690 | Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer | 000 | 1 | NIH | 10/28/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $400,000 ) |
| | 2022 | 2022 | SYNERGYS BIOTHERAPEUTICS, INC. | 3189 DANVILLE BLVD STE 295 | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R44CA265690 | Development of Anti-EGFR-huEndo-P125A: A combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer | 000 | 1 | NIH | 9/20/2022 | $400,000 |
| | 2022 | 2019 | SYNERGYS BIOTHERAPEUTICS INC | 3189 DANVILLE BLVD | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R43CA240044 | Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein | 000 | 1 | NIH | 9/26/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = -$2,568 ) |
| | 2021 | 2019 | SYNERGYS BIOTHERAPEUTICS, INC. | 3189 DANVILLE BLVD STE 295 | ALAMO | CA | 94507-1986 | CONTRA COSTA | USA | R43CA240044 | Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein | 000 | 1 | NIH | 4/2/2021 | -$2,568 |
|
| Issue Date FY: 2019 ( Subtotal = $300,000 ) |
| | 2019 | 2019 | SYNERGYS BIOTHERAPEUTICS, INC | 1945 ARBOL GRANDE | WALNUT CREEK | CA | 94595-2347 | CONTRA COSTA | USA | R43CA240044 | Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer using Antibody Fusion Protein | 000 | 1 | NIH | 6/14/2019 | $300,000 |
| | 2019 | 2017 | SYNERGYS BIOTHERAPEUTICS, INC | 1945 ARBOL GRANDE | WALNUT CREEK | CA | 94595-2347 | CONTRA COSTA | USA | R43CA195882 | Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer | 000 | 1 | NIH | 6/27/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $300,000 ) |
| | 2017 | 2017 | SYNERGYS BIOTHERAPEUTICS, INC | 1945 ARBOL GRANDE | WALNUT CREEK | CA | 94595-2347 | CONTRA COSTA | USA | R43CA195882 | Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer | 001 | 1 | NIH | 9/20/2017 | $35,539 |
| | 2017 | 2017 | SYNERGYS BIOTHERAPEUTICS, INC | 1945 ARBOL GRANDE | WALNUT CREEK | CA | 94595-2347 | CONTRA COSTA | USA | R43CA195882 | Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer | 000 | 1 | NIH | 9/14/2017 | $264,461 |
|
|
